Get the Stockscreener App
16.58
0.78%
-0.13
Theravance Biopharma Inc stock is traded at $16.58, with a volume of 952.85K.
It is down -0.78% in the last 24 hours and up +1.97% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$16.71
Open:
$16.72
24h Volume:
952.85K
Relative Volume:
2.21
Market Cap:
$854.75M
Revenue:
$109.78M
Net Income/Loss:
$114.54M
P/E Ratio:
7.5206
EPS:
2.2046
Net Cash Flow:
$268.74M
1W Performance:
+0.55%
1M Performance:
+1.97%
6M Performance:
-8.80%
1Y Performance:
+56.12%
1-Day Range:
$16.48
$16.85
1-Week Range:
$16.21
$16.85
52-Week Range:
$10.44
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.58 | 861.45M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH) - GuruFocus
Understanding Momentum Shifts in (TBPH) - Stock Traders Daily
Theravance Biopharma SVP Rhonda Farnum sells $218,167 in shares By Investing.com - Investing.com South Africa
Theravance Biopharma Inc (TBPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theravance Biopharma (TBPH) SVP Rhonda Farnum sells 13,314 shares at ~$16 - Stock Titan
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theravance Biopharma Inc (TBPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Theravance Biopharma (NASDAQ: TBPH) director granted shares and 13,398-share option - Stock Titan
Theravance Biopharma (TBPH) director Susannah Gray receives new share and option grants - Stock Titan
Director at Theravance Biopharma (NASDAQ: TBPH) receives new share and option grants - Stock Titan
Theravance Biopharma Inc (TBPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
13,314 restricted shares listed for sale by TBPH (NASDAQ: TBPH) — Rule 144 notice - Stock Titan
Theravance Biopharma, Inc. 8-K Filing Details: Annual Meeting Results, Auditor Appointment, and Company Information (June 2026) - Minichart
Theravance Biopharma Shareholders Back Directors and Governance Plans - TipRanks
Theravance Biopharma (NASDAQ: TBPH) investors approve directors, auditor and pay plan - Stock Titan
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Theravance stock declines around 17% in three months: Here's why - MSN
Jones Trading Initiates Coverage of Theravance Biopharma (TBPH) with Buy Recommendation - MSN
TBPH Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineRevenue Surprise History - newsline.com
Avoiding Lag: Real-Time Signals in (TBPH) Movement - Stock Traders Daily
Theravance Biopharma (TBPH) Edges Lower Amid Mixed Technical Signals – Key Levels to MonitorEarnings Beat Stocks - newsline.com
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Discipline and Rules-Based Execution in TBPH Response - Stock Traders Daily
Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) CFO has 8,670 shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax - Stock Titan
Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill - Stock Titan
Theravance Biopharma (TBPH) Stock Analysis: +0.55% Gain — What to Watch 2026-05-20High Volume Stocks - newsline.com
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN
Behavioral Patterns of TBPH and Institutional Flows - Stock Traders Daily
TradingKey - TradingKey
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock? - TradingView
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - sharewise.com
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and Strategic Collaborations Point to Promising Future - DirectorsTalk Interviews
Theravance Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q1 Revenue $17.7M, vs. FactSet Est of $17.8M - marketscreener.com
Theravance Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Theravance Biopharma reports Q1 2026 revenue $17.7M, narrows net loss to $4.9M - TradingView
Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth - TradingView
Theravance Bio: Q1 Earnings Snapshot - KTVB
Theravance (NASDAQ: TBPH) targets $60–70M cash flow after major restructuring - Stock Titan
Theravance Biopharma: Confident Will Achieve $100 Million Milestone Payment Associated With 2026 Trelegy Net Sales >TBPH - Moomoo
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - ChartMill
MSN Money - MSN
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Theravance's Q4 earnings and revenues miss estimates - MSN
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):